OrbiMed
OrbiMed is one of the largest specialist healthcare investment platforms globally.
- Healthcare and biotechnology venture capital investor
- Healthcare & BioTech Venture Capital
- Tier I
Overview
OrbiMed is one of the largest specialist healthcare investment platforms globally. It invests across biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, and technology through strategies that include venture capital, growth equity, public equities, credit, royalties, and other forms of healthcare finance.
Its multi-strategy structure gives private companies access to a broad view of scientific development, pharmaceutical markets, clinical milestones, strategic transactions, and public-market conditions. That perspective is valuable where financing requirements change substantially as a company moves from early discovery through clinical development and commercialization. Within The Economy Wiki, the institution is connected to the Healthcare & Biotechnology Venture Capital market category.
Firm facts
| Institution | OrbiMed |
| Type | Healthcare and biotechnology venture capital investor |
| Headquarters | New York / San Francisco / Shanghai, United States / global platform |
| Founded | 1989 |
| Primary ranking focus | Healthcare & BioTech Venture Capital |
| Highest 2026 tier | Tier I |
Activities and investment capabilities
OrbiMed’s international presence also reflects the globalization of healthcare innovation. Scientific assets, clinical programs, pharmaceutical partners, and capital increasingly move between North America, Europe, and Asia, requiring investors with cross-border networks and regulatory awareness.
Life-sciences investing
Capital for therapeutics, diagnostics, medical devices and research platforms.
Clinical development
Support across scientific validation, trials, regulation and commercialization.
Healthcare innovation
Investment in care delivery, health technology and data-enabled medical businesses.
Strategy and market coverage
Stage and strategy coverage
Company formation through growth; translational research; clinical and commercial financing
Sector and market coverage
Biotechnology; therapeutics; diagnostics; medtech; digital health and healthcare services
Market position
OrbiMed fits Tier I because the scale, continuity, specialist depth, global reach, and venture relevance of its healthcare platform make it an institutional anchor, even though its activities extend well beyond venture capital alone.
OrbiMed is assessed within the Healthcare & Biotechnology Venture Capital framework. For wider market context, see The Mid-Market Advantage in Healthcare Private Equity.
Competitive context
OrbiMed is recognized Tier I in Top 30 Healthcare & BioTech Venture Capital 2026. The rankings compare institutions by market relevance, investment or operating capability, sector and stage expertise, institutional credibility and current activity. Comparable links support navigation and do not imply that every institution competes for every company, fund commitment or transaction.
Leadership and governance
Leadership, investment-committee composition and operating resources may change over time. Current information should be confirmed through the institution’s official website.
| Leadership area | Current source |
|---|---|
| Investment and operating leadership | Current team and governance information |
Corporate and public information
This profile refers to OrbiMed as the public-facing organization. Individual funds, management companies, advisers, lending entities, broker-dealers and regulated affiliates may use separate legal names across jurisdictions.
Corporate and disclosure information
| Organization | OrbiMed |
| Headquarters | New York / San Francisco / Shanghai, United States / global platform |
| Public website | www.orbimed.com |
| Profile basis | Public institutional information and Capital Ranking editorial research |
Ranking recognition
Related Economy analysis
Selected Economy Markets articles provide context for the venture, financing, diligence and private-market themes relevant to this institution:
- The Mid-Market Advantage in Healthcare Private Equity
- Growth Equity vs Venture Capital and Buyouts: Key Differences
- Private Equity Technology Due Diligence in the AI Era
